ALB and neoplasm with perivascular epithelioid cell differentiation: On 23 November 2021, the FDA approved Fyarro®, an albumin-bound NP formulation of sirolimus, to treat locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).